S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Lots of sound and fury on US debt, but not a crisis — yet
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Is This The End of Capitalism? (Ad)
Challenge for Tunisian democracy: Getting voters to show up
Is tipping getting out of control? Many consumers say yes
Is This The End of Capitalism? (Ad)
FTX's Sam Bankman-Fried, DOJ tussle over his communications
TV anchors T.J. Holmes, Amy Robach leave ABC amid romance
NASDAQ:RGNX

REGENXBIO - RGNX Stock Forecast, Price & News

$23.13
+0.13 (+0.57%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$22.75
$23.29
50-Day Range
$21.67
$24.55
52-Week Range
$18.69
$35.73
Volume
295,183 shs
Average Volume
287,628 shs
Market Capitalization
$1.00 billion
P/E Ratio
14.92
Dividend Yield
N/A
Price Target
$41.43

REGENXBIO MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
79.1% Upside
$41.43 Price Target
Short Interest
Bearish
7.92% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
0.37mentions of REGENXBIO in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.32) to ($3.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

261st out of 1,054 stocks

Biological Products, Except Diagnostic Industry

40th out of 170 stocks


RGNX stock logo

About REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Stock News Headlines

SVB Leerink Cuts REGENXBIO (NASDAQ:RGNX) Price Target to $14.00
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
REGENXBIO ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Regenxbio (RGNX) Reports Q3 Loss, Lags Revenue Estimates
See More Headlines
Receive RGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.

RGNX Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
372
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.43
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+79.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$127.84 million
Pretax Margin
18.12%

Debt

Sales & Book Value

Annual Sales
$470.35 million
Cash Flow
$3.35 per share
Book Value
$17.87 per share

Miscellaneous

Free Float
37,796,000
Market Cap
$1.00 billion
Optionable
Optionable
Beta
0.99

Key Executives

  • Mr. Kenneth T. MillsMr. Kenneth T. Mills (Age 48)
    Pres, CEO & Director
    Comp: $1.72M
  • Mr. Vittal K. Vasista (Age 55)
    Exec. VP & Chief Financial Officer
    Comp: $1.25M
  • Mr. Curran M. Simpson M.S. (Age 61)
    Exec. VP and Chief Operations & Technology Officer
    Comp: $924.95k
  • Dr. Olivier Danos Ph.D. (Age 65)
    Exec. VP & Chief Scientific Officer
    Comp: $842.08k
  • Mr. Patrick J. Christmas II (Age 52)
    J.D., Exec. VP & Chief Legal Officer
    Comp: $1.11M
  • Ms. Tricia Truehart
    VP of Investor Relations & Corp. Communications
  • Mr. Andrew Yost
    VP of Corp. Devel.
  • Ms. Shiva G. Fritsch
    Chief People Officer
  • Dr. Laura A. Coruzzi J.D. (Age 70)
    Ph.D., Sr. VP of Intellectual Property
  • Dr. Ram Palanki Pharm.D.
    Sr. VP of Commercial Strategy & Operations













RGNX Stock - Frequently Asked Questions

Should I buy or sell REGENXBIO stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RGNX shares.
View RGNX analyst ratings
or view top-rated stocks.

What is REGENXBIO's stock price forecast for 2023?

6 brokerages have issued 12 month price targets for REGENXBIO's shares. Their RGNX share price forecasts range from $14.00 to $61.00. On average, they expect the company's stock price to reach $41.43 in the next twelve months. This suggests a possible upside of 79.1% from the stock's current price.
View analysts price targets for RGNX
or view top-rated stocks among Wall Street analysts.

How have RGNX shares performed in 2023?

REGENXBIO's stock was trading at $22.68 at the beginning of the year. Since then, RGNX shares have increased by 2.0% and is now trading at $23.13.
View the best growth stocks for 2023 here
.

When is REGENXBIO's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RGNX earnings forecast
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) issued its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.55) by $0.20. The biotechnology company earned $26.51 million during the quarter, compared to analysts' expectations of $29.77 million. REGENXBIO had a trailing twelve-month return on equity of 12.22% and a net margin of 15.34%.

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Block (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a number of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.24%), Harbor Capital Advisors Inc. (0.06%), SummerHaven Investment Management LLC (0.06%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.05%) and Maryland State Retirement & Pension System (0.04%). Insiders that own company stock include Allan M Fox, Curran Simpson, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Steve Pakola, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends
.

How do I buy shares of REGENXBIO?

Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $23.13.

How much money does REGENXBIO make?

REGENXBIO (NASDAQ:RGNX) has a market capitalization of $1.00 billion and generates $470.35 million in revenue each year. The biotechnology company earns $127.84 million in net income (profit) each year or $1.55 on an earnings per share basis.

How many employees does REGENXBIO have?

The company employs 372 workers across the globe.

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The official website for the company is www.regenxbio.com. The biotechnology company can be reached via phone at (240) 552-8181 or via email at ir@regenxbio.com.

This page (NASDAQ:RGNX) was last updated on 1/29/2023 by MarketBeat.com Staff